Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zhiling Yan

Showing results (101-110 of 118) with videos related to

Pageof 12
Sort By:
Nature Communications|April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trialMing Shi, Jiaojiao Wang, Hongming Huang, et al.
American Journal of Hematology|August 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapyYuekun Qi, Hujun Li, Kunming Qi, et al.
Nature Medicine|August 7, 2024
A generalist vision-language foundation model for diverse biomedical tasksKai Zhang, Rong Zhou, Eashan Adhikarla, et al.
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trialDian Zhou, Qian Sun, Jieyun Xia, et al.
Blood|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary diseaseDian Zhou, Yuekun Qi, Sha Ma, et al.
Blood|March 26, 2022
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSLYuekun Qi, Mingfeng Zhao, Yongxian Hu, et al.
Blood Advances|September 29, 2021
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myelomaYing Wang, Chunrui Li, Jieyun Xia, et al.
Cell Reports. Medicine|November 20, 2025
Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learningPeng Jin, Dan Wang, Jie Shen, et al.
Frontiers in Immunology|March 12, 2021
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell TreatmentZhiling Yan, Huanxin Zhang, Jiang Cao, et al.
Blood|March 16, 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myelomaSha Ma, Jieyun Xia, Miao Zhang, et al.
Pageof 12

Showing results (101-110 of 118) with videos related to

Sort By:
Pageof 12
Nature Communications|April 20, 2024
Bispecific CAR T cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trialMing Shi, Jiaojiao Wang, Hongming Huang, et al.
American Journal of Hematology|August 28, 2024
Clinical outcomes and microenvironment profiling in relapsed/refractory multiple myeloma patients with extramedullary disease receiving anti-BCMA CAR T-cell-based therapyYuekun Qi, Hujun Li, Kunming Qi, et al.
Nature Medicine|August 7, 2024
A generalist vision-language foundation model for diverse biomedical tasksKai Zhang, Rong Zhou, Eashan Adhikarla, et al.
The Lancet. Haematology|July 26, 2024
Anti-BCMA/GPRC5D bispecific CAR T cells in patients with relapsed or refractory multiple myeloma: a single-arm, single-centre, phase 1 trialDian Zhou, Qian Sun, Jieyun Xia, et al.
Blood|May 21, 2026
Anti-BCMA/GPRC5D CAR T in relapsed or refractory multiple myeloma patients with extraosseous extramedullary diseaseDian Zhou, Yuekun Qi, Sha Ma, et al.
Blood|March 26, 2022
Efficacy and safety of CD19-specific CAR T cell-based therapy in B-cell acute lymphoblastic leukemia patients with CNSLYuekun Qi, Mingfeng Zhao, Yongxian Hu, et al.
Blood Advances|September 29, 2021
Humoral immune reconstitution after anti-BCMA CAR T-cell therapy in relapsed/refractory multiple myelomaYing Wang, Chunrui Li, Jieyun Xia, et al.
Cell Reports. Medicine|November 20, 2025
Precision prediction of venetoclax-azacitidine treatment efficacy in acute myeloid leukemia via integrative drug screening and machine learningPeng Jin, Dan Wang, Jie Shen, et al.
Frontiers in Immunology|March 12, 2021
Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell TreatmentZhiling Yan, Huanxin Zhang, Jiang Cao, et al.
Blood|March 16, 2025
Genetic and epigenetic mechanisms of GPRC5D loss after anti-GPRC5D CAR T-cell therapy in multiple myelomaSha Ma, Jieyun Xia, Miao Zhang, et al.
Pageof 12